[HTML][HTML] Chimeric antigen receptor T cells in refractory B-cell lymphomas
…, J Svoboda, EA Chong, SD Nasta… - … England Journal of …, 2017 - Mass Medical Soc
Background Patients with diffuse large B-cell lymphoma or follicular lymphoma that is refractory
to or that relapses after immunochemotherapy and transplantation have a poor prognosis…
to or that relapses after immunochemotherapy and transplantation have a poor prognosis…
[HTML][HTML] Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis
…, C Timlin, D Landsburg, A Winter, SD Nasta… - …, 2018 - ncbi.nlm.nih.gov
Clinical trials that led to ibrutinib’s approval for the treatment of chronic lymphocytic leukemia
showed that its side effects differ from those of traditional chemotherapy. Reasons for …
showed that its side effects differ from those of traditional chemotherapy. Reasons for …
T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy
…, SP Susanibar Adaniya, J Svoboda, SD Nasta… - Nature Medicine, 2024 - nature.com
We report a T cell lymphoma (TCL) occurring 3 months after anti-CD19 chimeric antigen
receptor (CAR) T cell immunotherapy for non-Hodgkin B cell lymphoma. The TCL was …
receptor (CAR) T cell immunotherapy for non-Hodgkin B cell lymphoma. The TCL was …
[HTML][HTML] Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease
…, AW Loren, NV Frey, SD Nasta… - … England Journal of …, 2012 - Mass Medical Soc
Background Graft-versus-host disease (GVHD) is a major barrier to successful allogeneic
hematopoietic stem-cell transplantation (HSCT). The chemokine receptor CCR5 appears to …
hematopoietic stem-cell transplantation (HSCT). The chemokine receptor CCR5 appears to …
Efficacy and safety of hydroxychloroquine vs placebo for pre-exposure SARS-CoV-2 prophylaxis among health care workers: a randomized clinical trial
…, DV Babushok, AC Huang, SD Nasta… - JAMA internal …, 2021 - jamanetwork.com
Importance Health care workers (HCWs) caring for patients with coronavirus disease 2019 (COVID-19)
are at risk of exposure to severe acute respiratory syndrome coronavirus 2 (SARS…
are at risk of exposure to severe acute respiratory syndrome coronavirus 2 (SARS…
Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy
CD19-directed chimeric antigen receptor–modified (CAR T) T cells achieve durable remissions
in about 30% to 40% of relapsed/refractory large B-cell lymphomas. T-cell exhaustion …
in about 30% to 40% of relapsed/refractory large B-cell lymphomas. T-cell exhaustion …
Outcomes of patients with relapsed/refractory diffuse large B‐cell lymphoma with progression of lymphoma after autologous stem cell transplantation in the rituximab …
SJ Nagle, K Woo, SJ Schuster, SD Nasta… - American journal of …, 2013 - Wiley Online Library
Salvage chemotherapy followed by autologous stem cell transplant (ASCT) remains the
current standard of care for patients with relapsed or refractory diffuse large B‐cell lymphoma (…
current standard of care for patients with relapsed or refractory diffuse large B‐cell lymphoma (…
[HTML][HTML] A clone-directed approach may improve diagnosis and treatment of proliferative glomerulonephritis with monoclonal immunoglobulin deposits
…, SM Kobrin, DT Vogl, AG Wasserstein, SD Nasta… - Kidney International, 2018 - Elsevier
The optimal treatment for the monoclonal gammopathies of renal significance is not known,
but there is consensus among experts that treatment should be specific for the underlying …
but there is consensus among experts that treatment should be specific for the underlying …
Bridging radiation therapy before commercial chimeric antigen receptor T-cell therapy for relapsed or refractory aggressive B-cell lymphoma
…, DJ Landsburg, J Svoboda, SD Nasta… - International Journal of …, 2020 - Elsevier
Purpose CD19-targeting chimeric antigen receptor T-cell (CART) therapy has emerged as a
promising treatment for relapsed/refractory aggressive B-cell lymphoma (r/rABL), …
promising treatment for relapsed/refractory aggressive B-cell lymphoma (r/rABL), …
A phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemia
…, EA Stadtmauer, SC Goldstein, NV Frey, SD Nasta… - Clinical Cancer …, 2009 - AACR
Purpose: Inhibiting mammalian target of rapamycin (mTOR) signaling in acute myelogenous
leukemia (AML) blasts and leukemic stem cells may enhance their sensitivity to cytotoxic …
leukemia (AML) blasts and leukemic stem cells may enhance their sensitivity to cytotoxic …
